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Abstract Recurrent respiratory papillomatosis (RRP) is a
chronic and diYcult to treat disease of the larynx. In 1998,
the Wrst article was published that described the use of the
antiviral substance cidofovir to treat this disease. Although
the results are promising, there remains some concern about
the potential carcinogenicity of cidofovir. There is a
demand for a qualitative review of the side-eVects of this
medicine. In this review, the side-eVects of cidofovir are
investigated. Special attention was given to the potential
carcinogenicity of cidofovir. For this review a search is per-
formed in PubMed and EMBASE for relevant articles in
which the use of intralesional cidofovir for patients with
RRP is described. Eventually, 31 articles could be included
for this review. In these articles a total of 188 patients with
RRP were described who underwent therapy with intrale-
sional cidofovir. Five of these patients have developed dys-
plasia of the larynx during the treatment with cidofovir.
This is a percentage of 2.7. This percentage is concurrent
with the incidence of spontaneous malignant degeneration
of RRP (2–3%). Based on this review, it can be concluded
that the use of intralesional cidofovir does not increase the
risk of laryngeal dysplasia. Apart from the articles that
describe the intralesional administration of cidofovir, some
articles have been published in which the use of intrave-
nous cidofovir is described as a therapy for RRP. There-
fore, a summary is given on the side-eVects of intralesional
cidofovir as well as a summary on the reported side-eVects
of the intravenous administration of cidofovir. Based on the
outcomes of this review, recommendations are given for a
safe use of cidofovir for treatment of recurrent respiratory
papillomatosis in the future.
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Introduction
Recurrent respiratory papillomatosis (RRP) is a chronic
disease of the larynx which is diYcult to treat. The disease
is caused by an infection with human papilloma viruses
(HPV). In most cases, the HPV-subtypes 6 and 11 are
found. Rarely the subtypes 16 and 18 are identiWed [48].
The symptoms of this uncommon disease may vary from
hoarseness to severe obstruction of the airway. In 1998, the
Wrst article was published that described the oV-label use of
cidofovir to treat RRP [51].
Cidofovir is a cytosine nucleotide analogue with antivi-
ral activity that is approved by the US Food and Drug
Administration (FDA) for the treatment of cytomegalovirus
(CMV)-retinitis in persons with acquired immunodeW-
ciency syndrome. For the treatment of CMV-retinitis the
cidofovir is administered intravenously in a dose of 5 mg/
kg. Since 1998 several studies have been published in
which the results of cidofovir in the treatment of RRP were
analysed [6, 12, 20, 30, 36, 42, 43, 45, 48]. In most of these
studies the therapy with intralesional cidofovir proved to be
eVective.
Although few side-eVects of cidofovir have been
reported there is some concern about the potential carcino-
genicity of cidofovir. A study in rats has shown a signiW-
cant increase in mammary adenocarcinomas [24]. There
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have also been some reports of dysplasia in humans after
the use of intralesional cidofovir [20, 48, 51, 55]. How-
ever, spontaneous malignant degeneration of RRP is
possible. The reported incidence of this malignant degen-
eration is 2–5% [29, 51]. For these percentages no distinction
was made between diVerent HPV-subtypes. Spontaneous
malignant degeneration occurs in both juvenile-onset
RRP and adult-onset RRP and carries a dismal prognosis
[29].
Malignant transformation happens more often in patients
who have a history of smoking or radiation [5]. HPV-types
16 and 18 are considered high-risk types because they are
frequently associated with severe atypia and invasive carci-
noma in uterine cervical epithelium [34]. Nevertheless, sev-
eral articles have been published in which only the HPV-
subtypes 6 and 11 were found in patients with RRP that had
undergone malignant degeneration [8, 16, 27, 31, 34, 41,
44, 49]. The role of cidofovir in malignant degeneration of
RRP remains unclear. Because of the increasing use of
cidofovir for RRP, there is a demand for a qualitative
review of the side-eVects of this drug.
In this review, a summary is presented about the
reported side-eVects of cidofovir. Furthermore, the reported
cases of dysplasia in humans after the use of intralesional
cidofovir are compared to the total number of patients
treated with cidofovir that have been reported in the litera-
ture.
Materials and methods
A search was performed for articles that describe the use of
intralesional cidofovir in patients with RRP. The Wrst
search was performed in PubMed (1966 to August 2007):
#1. Cidofovir (laryngeal OR respiratory) AND papilloma-
tosis
#2. Cidofovir [Substance Name]
#3. Papilloma [Mesh]
#4. (“cidofovir” [Substance Name]) AND (“Papil-
loma”[Mesh])
#5. #1 OR #4
Sixty-three articles were found. The following inclusion
criteria were applied:
• use of intralesional cidofovir as a primary or adjuvant
therapy in the larynx in human patients with RRP;
• description of the used dosage of cidofovir;
• description of observed side-eVects;
• study designs have to be randomized controlled trials
(RCTs), comparative studies, case series or case reports.
After selection with the above criteria a total of 28 articles
could be included for this review.
A search in EMBASE (1966 to August 2007) was also
performed:
#1. Cidofovir AND (‘laryngeal papillomatosis’ OR
‘respiratory papillomatosis’)
This way 104 articles were found from which 57 were
also found in the PubMed search. The other 47 articles
were screened with the above inclusion criteria. Another
three articles could be included to a total of 31 articles for
this review. Reference lists from relevant articles, including
other reviews, were searched. No articles were excluded
due to language.
The PubMed search that included 63 articles was also
scanned for articles that describe other ways of application
of cidofovir. Four articles were found that describe the
intravenous use of cidofovir. In one article the cidofovir
was nebulized.
Results
Thirty-one original articles met the original inclusion crite-
ria. They comprised 1 case-control series, 26 case-series, 4
case-reports, and no randomized controlled trials. A sum-
mary of the articles is presented in Table 1.
Six of the 31 included articles proved to have an overlap
in patient population with one of the other articles. When
corrected for this overlap a total of 188 patients remained.
The mean age of these patients is 26 years with a range of
1–85 years.
The patient population consisted of 98 males (52%) and
69 females (37%). In 21 patients (11%) the gender was not
reported. Of this population, 104 patients (55%) were
adults (above 18 years of age) and 84 patients (45%) were
children (under 18 years of age). Adult-onset RRP was
diagnosed in 53 patients (28%) and 89 patients (47%) were
diagnosed with juvenile-onset RRP. In 46 patients (25%) it
was not noted at what age the disease started.
Side-eVects of cidofovir
The included articles have reported few side-eVects. In the
report of Snoeck et al. [51], two patients developed an
immediate cutaneous rash after cidofovir injection on one
occasion. It is unclear if the rash was a direct side-eVect of
the cidofovir. Such rashes are also known to happen to
patients under total intravenous anaesthesia. Rashes were
not further observed during the following sessions of treat-
ment of these two patients.
In the same report one patient experienced a headache
after each injection, which responded to symptomatic ther-
apy. Another patient reported precordialgia on the days fol-
lowing each of his three injections. This patient was known
for coronary insuYciency, but his electrocardiogram (ECG)Eur Arch Otorhinolaryngol (2008) 265:871–879 873
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did not show any changes. InXammation, scarring or Wbro-
sis have not been observed in any of the patients in this
report.
Bielamowicz et al. [6] reported a local inXammatory
response after injection with cidofovir. In this study, 14
patients received cidofovir in a concentration of 4.17–
6.25 mg/ml. The inXammatory response was frequently
observed during the 7th to 14th-day period after each
injection. No new areas of scarring, web formation, or
impaired vibration of the vocal fold mucosa were identiWed
in this study.
In a report by Lee et al. [30] in which 13 patients were
treated with cidofovir, 3 patients were found to have signiW-
cant vocal fold scarring. In addition, one patient developed
a supraglottic web after bilateral false vocal fold injections.
The authors note that it is hard to say if the vocal fold scarring
Table 1 Summary of reviewed studies
Six articles are shown in italics because of an overlap in patient population. The data of the patients from these articles are not added to the total
number of patients
N/A not available
a Adults (above 18 years of age), children (under 18 years of age)
b Adult-onset (AO start of RRP above 18 years of age), Juvenile-onset (JO start of RRP under 18 years of age)
Reference Design No. of patients Mean age at start 
cidodovir (range)
Adults (A)/
children (C)a
Type adult/juvenile 
papillomatosisb
Gender male 
(M)/female (F)
Pudszuhn et al. [48]  Case series 10 45 (2–74)  8 A/2 C 7 AO/3 JO 5 M/5 F
Naiman et al. [36]  Case series 16 12 (1–34) 4 A/12 C JO 7 M/9 F
Naiman et al. [35]  Case series 19 36 (24–52) 19 A AO 13 M/6 F
Chung et al. [12]  Case series 11 7 (N/A) 11 C JO 7 M/4 F
Sheahan et al. [50]  Case series 4 8 (3–16) 4 C JO 4 F
Pontes et al. [43]  Case series 10 40 (27–58) 10 A N/A N/A
Dikkers [20]  Case series 9 36 (22–50) 9 A 7 AO/2 JO 6 M/3 F
Wemer et al. [55]  Case report 1 28 1 A N/A 1 F
Palomar et al. [40]  Case report 1 4 1 C JO 1 M
de Bilderling et al. [18]  Case report 1 8 1 C JO 1 F
Askew et al. [3]  Case series 4 10 (8–14) 4 K JO 2 M/2 V
Lee et al. [30]  Case series 16 33 (9–68) 13 A/3 C 12 AO/4 JO 12 M/4 F
Co et al. [13]  Case series 5 36 (30–43) 5 A AO 1 M/4 F
Mandell et al. [32]  Case-control series 7 (incl. 3 controls) 7 (1–14) 4 C  JO 1 M/3 F
Peyton et al. [42]  Case series 11 5 (3–13) 11 C JO N/A
Avelino et al. [4]  Case series 5 5 (3–9) 5 K JO 3 M/2 V
Naiman et al. [37]  Case series 26 28 (5–56) 19 A/7 C 16 AO/10 JO 15 M/11 F
Neumann et al. [39] Case series 7 48 (5–70) 6 A/1 C 5 AO/2 JO 3 M/4 F
Chhetri et al. [11]  Case series 5 5 (1–11) 5 C JO 3 M/2 F
Milczuk [33]  Case series 4 4 (3–7) 4 C JO 2 M/2 F
Pransky et al. [45]  Case series 11 5 (2–9) 11 C JO 7 M/4 F
Akst et al. [1] Case series 11  7 (2–14) 11 C JO 7 M/4 F
Coulombeau et al. [14] Case series 26  28 (5–56) 19 A/7 C 16 AO/10 JO 15 M/11 F
El Hakim et al. [22]  Case series 2 4 (3–4) 2 C JO 1 M/1 F
Bielamowicz et al. [6]  Case series 13 47 (18–85) 13 A N/A 9 M/4 F
Chhetri et al. [9]  Case series 5 44 (21–62) 5 A N/A 5 M
El Aatmani et al. [21]  Case report 1 10 1 K JO 1 V
Pransky et al. [46]  Case series 10  5 (2–9) 10 C JO 8 M/2 F
Wilson et al. [56]  Case series 3 41 (30–63) 3 A AO 3 M
Pransky et al. [47] Case series 5  3 (2–5) 5 C JO 4 M/1 F
Snoeck et al. [51]  Case series 17 44 (11–77) 14 A/3 C N/A 10 M/7 F
Total 188 26 (1–85) 104 A/84 C 53 AO/89 
JO/46/N/A
98 M/69 
F/21 N/A874 Eur Arch Otorhinolaryngol (2008) 265:871–879
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in this study should be attributed to the cidofovir or the
repeated microlaryngoscopy.
One case was reported in which a compromised airway
following treatment with cidofovir occurred [18]. An 8-
year-old female patient developed glottis oedema after int-
ralesional injection with cidofovir. This led to severe post-
operative stenosis of the airway requiring intubation and
24 h mechanical ventilation.
One article was published in which the RRP was treated
with percutaneous injection of cidofovir under local anaes-
thesia [9]. All patients in this study reported a mild stinging
sensation as the medication was administered. There were
no other complications related to the injection.
In the studies that monitored blood chemistry, no eVect
was noted of intralesionally injected cidofovir on haemato-
logical and chemical parameters in blood [33, 37, 38, 45,
51]. In two studies, the plasma cidofovir concentration after
intralesional administration was measured [38,  51]. The
used concentration of cidofovir in the Wrst study was
2.5 mg/ml. The measured concentrations of cidofovir in
plasma ranged from 0.36 to 0.6 g/ml [51]. In the second
study, a concentration of cidofovir of 7.5 mg/ml was used.
The measured plasma cidofovir concentrations in this study
ranged from 0.04 to 3.69 g/ml [38]. In this last report, a
linear relationship was found between plasma concentra-
tion and dose of cidofovir in children. In adults, this rela-
tionship was not found: they showed a greater diVusion
than children with great individual variation. Therefore, the
authors of this last report recommend that intralesional
cidofovir should be used at a dose below that reported to
lead to toxicity in IV use (3 mg/kg) [54].
The measured plasma cidofovir concentrations in the
two above studies are remarkably lower than those
achieved with systemic administration of cidofovir. In a
pharmacokinetic study peak serum cidofovir concentrations
of 7 and 24 g/ml were found after cidofovir infusions of,
respectively, 3 and 10 mg/kg [15].
Carcinogenicity of cidofovir
There have been some reports of dysplasia in humans after
the use of intralesional cidofovir [20, 48, 51, 55]. To assess
the potential carcinogenicity of cidofovir, a summary of the
used dosage and concentration of cidofovir and reported
dysplasia in the diVerent articles is presented in Table 2.
A form of dysplasia has been reported in Wve patients.
These Wve cases will be discussed in more detail in the sec-
tion below.
In the report by Pudszuhn et al. [48], a 58-year-old
female patient developed dysplasia during treatment with
intralesional cidofovir. This patient had histologically con-
Wrmed adult-onset papillomatosis without known radiation
or tobacco abuse. After Wve injections with cidofovir to a
total dose of 30 mg in 4 months, a histological check-up
revealed severe dysplasia of the epithelium with local tran-
sition to a carcinoma in situ. Therapy with cidofovir was
discontinued. She was checked microlaryngoscopically and
histologically without further carcinoma Wndings. In the
clinical check-up 19 months after diagnosis, there was no
evidence of a papilloma or malignoma. Virus typing was
not performed.
In the report by Dikkers [20] a case of dysplasia was also
found. From the original biopsies of this 45-year-old non-
smoking male patient with adult-onset papillomatosis the
HPV-subtypes 6 and 11 were identiWed. He received a total
dose of 83.5 mg cidofovir in six injections. A biopsy
6 months post-cidofovir revealed moderate epithelial dys-
plasia without invasive growth. He had a pre-existent ante-
rior glottic web, which theoretically might have hampered
dilution of the injected cidofovir because of the decreased
local blood Xow.
Wemer et al. [55] describe the case of a 28-year-old
female patient who developed dysplasia during treatment
with intralesional cidofovir. Her initial pathological diagno-
sis was papillomatosis with mild dysplasia. She had no his-
tory of irradiation or cigarette smoking. After 17 months of
treatment biopsy of a papilloma resection demonstrated
moderate dysplasia. After 28 months of cidofovir-therapy
biopsy demonstrated both moderate and severe dysplasia
within the papillomas. Use of cidofovir was discontinued at
this time. Three months after discontinuation of treatment
persistence of moderate and severe dysplasia was demon-
strated. All lesions submitted to biopsy were genotyped and
found to be HPV-6-positive.
In the report by Snoeck et al. [51], two patients are
described who showed lesions microscopically compatible
with verrucous carcinoma. Both were smoking, male
patients: one was 66-year-old, the other 77-year-old. They
had received cidofovir for, respectively, 6.5 and 4.5 months.
Additional investigation, however, has revealed that the
pre-treatment biopsy specimens of these two patients
showed atypical cells that may have actually been verru-
cous carcinoma rather than RRP [47]. Late biopsies taken
from the 66-year-old patient were characterized by persis-
tent hyperkeratosis, but in situ hybridization for HPV was
negative. In the 77-year-old patient HPV typiWcation was
not performed.
In Wve of the 188 patients in this review, moderate to
severe dysplasia has been reported during or after intrale-
sional treatment with cidofovir. This means that in 2.7% of
the patients treated with cidofovir dysplasia or malignant
degeneration has occurred. This percentage is concurrent
with the incidence of spontaneous malignant degeneration of
RRP (2–3%). The patients in whom dysplasia has occurred
consist of three adult male and two adult female patients
with a mean age of 55 (28–77) years. Two patients haveEur Arch Otorhinolaryngol (2008) 265:871–879 875
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adult-onset RRP; in three patients was not noted when the
disease started. The dysplasia was observed after an average
period of 8 months of cidofovir treatment with a range of
4–17 months. In two of the Wve patients the cumulative dose
of cidofovir is known. These two patients received amounts
of 30 and 83.5 mg cidofovir. The HPV-subtype could be
identiWed in two patients: once only subtype 6 was found and
once both subtypes 6 and 11 were found.
Systemic treatment with cidofovir
Apart from the articles that describe the use of intralesional
cidofovir, four articles have been published that describe the
use of intravenous cidofovir as treatment for RRP [2, 17, 18,
53]. The four reported cases all had pulmonary extension of
their RRP. They received the intravenous injections with
cidofovir at a dose of 5 mg/kg. In all cases the intravenous
injections were associated with hyperhydration and probene-
cid in order to diminish nephrotoxicity. From the four
patients with RRP that have been treated with intravenous
cidofovir one displayed side-eVects. She developed leukope-
nia and partial alopecia on her combination therapy of
cidofovir and interferon [17]. At that time she had received
34 intravenous injections with cidofovir in a period of
16 months. The therapy was well tolerated in the other three
patients. They received a total of 27, 23 and 37 intravenous
injections in a period of, respectively, 14, 12 and 27 months
[2,  18,  53]. In the treatment of CMV-retinitis of AIDS-
patients, nefrotoxicity and neutropenia have been reported as
side-eVects of the therapy with intravenous cidofovir [28].
Nebulized treatment with cidofovir
Apart from the four articles in which cidofovir was adminis-
tered intravenously to treat the pulmonary extension of
RRP, one article is published in which a case is described
where the cidofovir was nebulized to reach the pulmonary
lesions [26]. In this case a girl presented at 11 months of age
with respiratory failure and stridor due to her RRP for which
a tracheostomy was performed. To reach the lung papillo-
mas cidofovir was nebulized through her tracheostomy tube
(20 mg/ml, 4 ml, 3 times/week). Her only complication was
hemoptysis that resolved with decreasing the dosage to
10 mg/ml, 4 ml, 3 times/week. Her lower airway lesions
responded and diminished in size. Currently, her lower air-
way lesions have visually disappeared. She is maintained on
cidofovir two times a week without complications.
Discussion
In the literature, three diVerent ways to administer cidofovir
as treatment for RRP have been described. In most cases,
the cidofovir is administered intralesionally. Four cases
have been described in which the cidofovir was adminis-
tered intravenously and in one case the cidofovir was nebu-
lized to treat RRP.
In the thirty-one articles that describe the use of intrale-
sional cidofovir few side-eVects have been reported. The
only reported side-eVects that have an evident causal rela-
tionship with the cidofovir injections are the local inXam-
matory responses in 14 adult patients described by
Bielamowicz et al. [6]. The development of a supraglottic
web in one patient and scarring of the vocal folds in three
patients described by Lee et al. [30] could have been caused
by the injections with cidofovir but could have also been
caused by the repeated microlaryngoscopy. One case is
described in which treatment with intralesional cidofovir in
an 8-year-old girl led to glottis oedema that required intuba-
tion [18].
In two studies, the plasma cidofovir concentration after
intralesional administration has been measured [38, 51].
The highest measured serum cidofovir concentration was
3.69 g/ml. This concentration was found in a child who
received a dose of 2.8 mg/kg. The concentration of 3.69 g/
ml is corresponding to a dose of 1 mg/kg in intravenous infu-
sion [38]. As the used dose of intralesional cidofovir for the
treatment of CMV-retinitis is 5 mg/kg, the serum cidofovir
concentrations in these patients are remarkably higher [15].
In none of the reviewed studies a concentration higher than
the recommended 3 mg/kg was administered in adults.
To assess the potential carcinogenicity of cidofovir, all
the articles that describe the use of intralesional cidofovir in
patients with RRP have been reviewed. This review showed
that dysplasia occurred in 2.7% of all patients with RRP
that have been treated with intralesional cidofovir. This per-
centage is concurrent with the reported incidence of sponta-
neous malignant degeneration of RRP (2–3%)[51]. Based
on the outcomes of this review it can be concluded that the
use of intralesional cidofovir does not increase the risk of
laryngeal dysplasia. The two patients with verrucous carci-
noma that have been described by Snoeck et al. [51] have
been included in this review. However, it remains uncertain
if the pre-treatment lesions of these two patients were not
verrucous carcinoma rather than RRP [47]. When these two
patients would be excluded from this review there would
have been three patients with dysplasia on a total of 186
treated patients. This corresponds to a percentage of 1.6.
Since it is not deWnitely sure that the verrucous carcinoma
was present before the start of therapy with cidofovir the
two patients have been included in our study. The follow-
up period of the included studies varied. It cannot be ruled
out that there are patients in which dysplasia has occurred
after the follow-up period.
In two of the Wve patients with dysplasia the HPV-sub-
type has been identiWed. In these two patients HPV-6 andEur Arch Otorhinolaryngol (2008) 265:871–879 877
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HPV-11 were found. The high-risk types HPV-16 and 18
were not present. This is not unusual, as becomes clear
from the various articles that have been published in which
only the HPV-subtypes 6 and 11 were found in patients
with RRP that had undergone malignant degeneration [8,
16, 27, 31, 34, 41, 44, 49].
The known cumulative dosages in the patients in which
dysplasia has occurred (30 and 83.5 mg) do not diVer from
the cumulative dosages that have been administered in
other studies. In one study, the mean cumulative dose is
even 348 mg [9]. A cumulative eVect on the development
of dysplasia is, therefore, unlikely.
The safety of intralesional injections with cidofovir has
also been evaluated in animals [10, 24, 52]. Chhetri et al. [10]
used a canine model to investigate the eVects of cidofovir. A
6-month period of intralaryngeal injection of cidofovir
induced dose-dependent localized toxic injury to muscle and
induced vocal fold atrophy and scarring. These eVects
appeared to be irreversible in the animals that received a dose
higher than 20 mg of cidofovir. There were no clinically sig-
niWcant changes in leukocyte count, renal parameters, elec-
trolytes, or liver function tests. No evidence of dysplasia,
metaplasia, or carcinoma of the vocal folds was observed.
Spiegel et al. [52] evaluated the local eVects of cidofovir
injection on cartilage in rabbits during 6 weeks. A total of
96 sites were injected with cidofovir in concentrations of 0,
5, 25, and 75 mg. One third of the injection sites showed a
gross change in appearance (mild to moderate crusting,
some with erythema), whereas two thirds showed no visible
change at any time during the 6 weeks. Although there was
a statistical likelihood for increased local change after
cidofovir injection, there was no correlation of severity
with injected dose.
In a 26-week intravenous toxicology study in which rats
received 0.6, 3, or 15 mg/kg cidofovir once weekly, a sig-
niWcant increase in mammary adenocarcinomas in female
rats was observed [24]. Furthermore, a signiWcant incidence
of Zymbal’s gland carcinomas in male and female rats was
seen at the high dose but not at the lower two doses.
Cidofovir caused no tumours in a 1-year monkey toxicity
study. In this study, cynomolgus monkeys received intrave-
nous cidofovir, alone and in conjunction with concomitant
oral probenecid, intravenously once weekly for 52 weeks.
They received doses resulting in exposures of approxi-
mately 0.7 times the human systemic exposure at the rec-
ommended dose of cidofovir.
The Wndings in rats raised the concern about the poten-
tial carcinogenicity of cidofovir. It is noteworthy, however,
that the development of mammary adenocarcinoma in rats
is a frequent occurrence in rat pharmacologic studies [19].
In the four cases in which the cidofovir was administered
intravenously the RRP had an aggressive course with pul-
monal extension. Pulmonary involvement of RRP can lead
to respiratory insuYciency and even death [45]. Few side-
eVects have occurred in the four cases in which the cidofo-
vir was administered intravenously [2, 17, 18, 53]. In one
case partial alopecia and leukopenia occurred after 34
injections with cidofovir in a period of 16 months [17].
Nefrotoxicity was not noted in the four described cases.
Therefore, pulmonary involvement of RRP seems a justi-
Wed indication for the intravenous administration of cidofo-
vir. The administration of oral probenecid and intravenous
hydration before and after each cidofovir dose remains
important.
Because there are no adequate and well-controlled stud-
ies in pregnant women and cidofovir has shown to be tera-
togenic and embryotoxic in animal studies, this medicine is
classiWed by the FDA as a pregnancy category C drug [25].
The FDA recommends using category C drugs only during
pregnancy if clearly needed [23]. Because RRP can also be
controlled with repeated microsurgery the use of cidofovir
during pregnancy can be avoided. It is noteworthy, how-
ever, that the recommendations of the FDA for cidofovir
during pregnancy are based on the systemic administration
of cidofovir.
In a combined in vitro and in vivo study on the teratoge-
nicity of cidofovir a cytostatic eVect on eukaryotic cells and
a generalized embryolethal eVect in pregnant rats was
found [7]. The cidofovir was administered to the rats in a
relatively high concentration of 20–100 mg/kg. For the int-
ralesional administration of cidofovir concentrations below
3 mg/kg are being used. As noted above the plasma cidofo-
vir concentrations after intralesional administration are
remarkably lower than those achieved with the systemic
administration of cidofovir [38]. Furthermore, no systemic
side-eVects have been reported during treatment with int-
ralesional cidofovir. Therefore, the question rises if terato-
genic eVects are indeed to be expected during the use of
intralesional cidofovir. More studies in the future are neces-
sary to answer this question. Until that time it remains rec-
ommended to be reserved with the use of intralesional
cidofovir during pregnancy.
Conclusion
Based on the published literature it can be concluded that
the therapy with intralesional cidofovir for patients with
RRP does not increase the risk of laryngeal dysplasia. Sys-
temic side-eVects have not been reported in patients who
have received intralesional cidofovir. Treatment with
intralesional cidofovir seems to be safe provided that the
regulations for this therapy are being followed. These regu-
lations comprehend that the intralesionally injected dose
of cidofovir in adults should be below 3 mg/kg. During
pregnancy, it is recommended to be reserved with the use878 Eur Arch Otorhinolaryngol (2008) 265:871–879
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of intralesional cidofovir. Pulmonary involvement of RRP
seems a justiWed indication for the intravenous administra-
tion of cidofovir.
The treatment with cidofovir should be given in a ter-
tiary care hospital because of the low incidence of RRP.
Furthermore, it remains important to monitor the potential
side-eVects of cidofovir and always histologically analyze
the biopsies taken from patients who received treatment
with cidofovir. The publication of encountered side-eVects
and occurrence of dysplasia during treatment with intrale-
sionally applied cidofovir is important for the evaluation of
the safety of cidofovir in the future.
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